Following a limited submission
AWMSG advice |
|||
| Status: Recommended | |||
Diamorphine hydrochloride (Ayendi®) is recommended as an option for use within NHS Wales for the treatment of acute severe nociceptive pain in children and adolescents 2 to 15 years of age in a hospital setting. Ayendi® nasal spray should be administered in the emergency setting by practitioners experienced in the administration of opioids in children and with the appropriate monitoring. |
|||
|
|||
Medicine details |
|||
| Medicine name | diamorphine hydrochloride (Ayendi®) | ||
| Formulation | 720 micrograms nasal spray and 1600 micrograms nasal spray | ||
| Reference number | 2406 | ||
| Indication | Treatment of acute severe nociceptive pain in children and adolescents 2 to 15 years of age in a hospital setting. Diamorphine hydrochloride nasal spray should be administered in the emergency setting by practitioners experienced in the administration of opioids in children and with appropriate monitoring |
||
| Company | Wockhardt UK Ltd | ||
| BNF chapter | Central nervous system | ||
| Submission type | Limited | ||
| Status | Recommended | ||
| Advice number | 1719 | ||
| NMG meeting date | 09/10/2019 | ||
| AWMSG meeting date | 13/11/2019 | ||
| Date of issue | 28/11/2019 | ||
| Further information This product has been discontinued by the manufacturer. |
|||